"bharat-biotech"

Bharat Biotech International Limited has partnered with UNICEF and Gavi to slash the price of its malaria vaccine, Mosqivac, by 40 per cent to EUR 5.50 per dose. This price drop will enable up to one million additional children to receive the complete four-dose course.

Pandorum Technologies has partnered with Bharat Biotech arm Nucelion Therapeutics to expand manufacturing of its exosome-based regenerative therapies across the Asia-Pacific region, strengthening regional supply, regulatory readiness and India’s biologics manufacturing capabilities

RTS,S was the first malaria vaccine recommended by the World Health Organization in 2021. The two companies said the price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins

Study findings have been published in the Science Direct, Vaccine journal 126998 to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority and lot-to-lot consistency of single component oral cholera vaccine

The Biolumpivaxin will help in disease surveillance to protect livestock from Lumpy Skin disease

Urges youth to recognise the wealth of scientific knowledge available, embrace fundamentals of science

Biolumpivaxin is a single vaccination regimen given once a year to cattle and buffaloes above 3 months of age.

To mitigate this global shortage of oral cholera vaccine, Bharat Biotech has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of Hillchol, a press release said

D. Sai Prasad, Chairman, CII Telangana & Executive Director, Bharat Biotech International, underscored the importance of the CII CFO Forum as a platform for finance professionals to exchange strategies and insights.

Bharat Biotech said that its Covid-19 vaccine Covaxin has an excellent safety record without any vaccine-associated incidents of blood clots, thrombocytopenia, etc.

Dr. Ella takes over from Adar C Poonawala, who held the post from 2019 to March 2024.

An agreement has been signed between Bharat Biotech International Limited (BBIL) and BBio wherein BBIL will procure drug substances for the production of OPV to be supplied within India and globally.

The clinical trials are being carried out by Bharat Biotech in collaboration with Biofabri, the noted vaccine developer from Spain.

Genome Valley: It is home to more than 200 companies with a scientific workforce of about 20,000 professionals

Dr Krishna M Ella released a book “Economics of Covid-19- Digital Health, Education and Psychology” at his office at Hyderabad

It is the world's first intranasal Covid-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose.

The vaccine manufacturer had already received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month for the nasal vaccine, the first of its kind in India.

NCOVACC is the world's first intranasal vaccine for COVID to receive approval for the primary two-dose schedule, and as a heterologous booster dose.

The availability of intranasal vaccine will strengthen the fight against the pandemic and broaden vaccine coverage.

Bharat Biotech on Monday announced that its iNCOVACC, its Covid vaccine in the form of nasal drops, has received approval from the CDSCO